BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 19345401)

  • 21. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
    Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
    Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
    Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
    Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
    Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
    Yan TD; Deraco M; Baratti D; Kusamura S; Elias D; Glehen O; Gilly FN; Levine EA; Shen P; Mohamed F; Moran BJ; Morris DL; Chua TC; Piso P; Sugarbaker PH
    J Clin Oncol; 2009 Dec; 27(36):6237-42. PubMed ID: 19917862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome.
    Fagotti A; Costantini B; Vizzielli G; Perelli F; Ercoli A; Gallotta V; Scambia G; Fanfani F
    Gynecol Oncol; 2011 Aug; 122(2):221-5. PubMed ID: 21543112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up.
    Fagotti A; Costantini B; Petrillo M; Vizzielli G; Fanfani F; Margariti PA; Turco LC; Piovano E; Scambia G
    Gynecol Oncol; 2012 Dec; 127(3):502-5. PubMed ID: 23022234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.
    Scaringi S; Kianmanesh R; Sabate JM; Facchiano E; Jouet P; Coffin B; Parmentier G; Hay JM; Flamant Y; Msika S
    Eur J Surg Oncol; 2008 Nov; 34(11):1246-52. PubMed ID: 18222622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
    J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
    Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A
    Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].
    Ferron G; Martinez A; Mery E; Querleu D; Thomas F; Chatelut E; Gladieff L
    Bull Cancer; 2009 Dec; 96(12):1243-52. PubMed ID: 19948452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
    Bristow RE; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Sironi A; Cabras A; Fumagalli L; Laterza B; Deraco M
    In Vivo; 2008; 22(1):153-7. PubMed ID: 18396799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.
    Manci N; Bellati F; Muzii L; Calcagno M; Alon SA; Pernice M; Angioli R; Panici PB
    Ann Surg Oncol; 2006 Dec; 13(12):1717-23. PubMed ID: 16957965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
    Bijelic L; Yan TD; Sugarbaker PH
    Ann Surg Oncol; 2007 Aug; 14(8):2281-8. PubMed ID: 17503156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.
    Nicoletto MO; Falci C; Pianalto D; Artioli G; Azzoni P; De Masi G; Ferrazzi E; Perin A; Donach M; Zoli W
    Gynecol Oncol; 2006 Feb; 100(2):318-23. PubMed ID: 16239023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.
    Munkarah AR; Coleman RL
    Gynecol Oncol; 2004 Nov; 95(2):273-80. PubMed ID: 15491746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.
    Gusani NJ; Cho SW; Colovos C; Seo S; Franko J; Richard SD; Edwards RP; Brown CK; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2008 Mar; 15(3):754-63. PubMed ID: 18080166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.